February 19, 2018

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Zacks Rank: 1-Strong Buy

$332.15 USD (As of 02/16/2018) Style Value: Growth: Momentum: VGM:

Target Price $383.00 Price, Consensus & Surprise

52 Week High-Low $543.55 - $313.53
20 Day Average
1,279,799
Volume

Beta 1.47
Market Cap 35.69 B
Dividend / Div Yld $0.00 / 0.00%
Medical -
Industry
Biomed..

184 / 265 (Bot

Industry Rank
31%)
Proj. EPS Growth (Q1) 54.11%
Proj. EPS Growth (F1) 14.28%

P/E (F1) 17.30

Last EPS Surprise 11.75%

Avg. Last 4 Surprises 9.15%

Next Report Date 5/3/2018

Earnings ESP 1.95%

Agreement Estimate Revisions (60 Days) Magnitude Consensus Estimate Trend (60 Days)

Q1 Q2 F1 F2 Q1 Q2 F1 F2
# of Analysts 12 11 14 13 Current 4.50 4.65 18.65 21.56

# of Revisions 5 5 13 9 7 Days Ago 4.50 4.65 18.65 21.56

# Up 4 4 12 8 30 Days Ago 3.96 4.38 17.16 20.46

# Down 1 1 1 1 60 Days Ago 3.82 4.29 16.77 20.29

Trend of
% Revision Agreement: 80% 80% 92% 89% Estimate
Revisions: +17.80% +8.39% +11.21% +6.26%

Industry Comparison Medical - Biomed.. | Position in Industry: 1 of 259 Industry Peers

REGN X Industry S&P 500 ALXN ILMN VRTX

Hist. EPS Growth (3-5 yrs) 14.78% 15.49% 7.09% 14.21% 20.40% NA
Proj. Sales Growth (F1/F0) 9.49% 14.08% 5.50% 12.56% 13.96% 22.48%
Net Margin 20.41% -268.34% 9.89% 12.48% 26.56% 10.59%
Return on Equity 28.48% -66.54% 16.01% 12.94% 21.71% 11.02%
Debt/Capital 10.27% 0.00% 41.98% 25.62% 33.78% 1.11%
P/E (F1) 17.30 25.84 17.64 19.70 49.97 96.10
Price/Sales (P/S) 6.08 18.40 2.55 7.52 12.24 16.40
Price/Book (P/B) 5.81 4.42 3.32 3.00 12.26 19.98
Price/Cash Flow (P/CF) 20.90 23.33 14.75 14.99 43.07 1,144.08
YTD % Price Change -11.65% 2.67% 0.86% 0.74% 4.90% 7.25%

Description Medical > Drugs > Medical - Biomedical And Genetics

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic
medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity,
rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.

Learn More about Zacks Rank and Style Scores